Sort by
Refine Your Search
-
Listed
-
Category
-
Employer
-
Field
-
researcher who is passionate about developing automated systems for microbiological research. The ideal candidate has: An MSc degree in bioengineering, biotechnology, microbiology, computer science, mechanical
-
Participation in a large European collaboration State-of-the-art research facilities A dedicated training program to broaden your expertise and enhance your skill set A doctoral scholarship for a period of one
-
for greener electronics.One of the obstacles still limiting the development of a sustainable organic electronics is the understanding of its operational and environmental stabilities. While the reactivity
-
Knowledge of electronics, programmable logic, and processing systems is an advantage Strong analytical and programming skills are required (Python, VHDL, Matlab, and C/C++). Prior proven experience in data
-
factors that accelerate material deterioration (e.g., hydrogen embrittlement, corrosion). The primary tasks include developing advanced multiphysics frameworks (finite element/phase-field methods
-
followed so far, and to suggest appropriate next steps. The key technology for developing this tool will be the IDP-Z3 reasoning engine . The research will be carried out within the Artificial Intelligence
-
URENIMOD (Ultrasound for Remote Neuroimaging and Modulation), a Ph.D. position is available at Ghent University from September 2025. The project aims to develop a minimally to non-invasive treatment
-
and grippers offer improved safety and adaptability but introduce new challenges in design and control. Their development is still largely bio-inspired and trial-and-error based. Integrating flight and
-
Prof. Raphaël Frank, and work in close collaboration with the academic and industrial partners in ongoing projects focusing on energy transition. This PhD project will focus on the development
-
of the biology that underlies cancer initiation, progression and metastatic dissemination with the ultimate goal to develop more effective and specific anti-cancer (combination) therapies. CCB is currently